Could a new scan unlock better breast cancer treatment?
NCT ID NCT06732336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special PET scan using a radioactive tracer called 89Zr-trastuzumab to find low levels of HER2 in metastatic breast cancer. Researchers aim to see if this scan can better detect tumors that might respond to newer drugs like Enhertu. The trial will involve 40 adults with HER2-low breast cancer, and results could help personalize treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-trastuzumab (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors see which tumors have low HER2, guiding personalized treatments like Enhertu for more patients.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply broadly. The imaging may not reliably detect all low-HER2 tumors, and there are no direct treatment benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre de recherche du CHUS
RECRUITINGSherbrooke, Quebec, J1H5N4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact